Followers | 160 |
Posts | 3933 |
Boards Moderated | 2 |
Alias Born | 07/08/2017 |
Saturday, March 21, 2020 1:39:57 PM
I doubled my position couple of days ago Around $1.25.
Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431, a cyclophilin inhibitor with antifibrotic and antiviral properties, may show some effect in the ongoing COVID-19 pandemic, according to Roth Capital Partners.
“We believe there is strong rationale for a non-immunosuppressive molecule like Hepion’s CRV431 to show some effect as an antiviral and antifibrotic in the ongoing COVID-19 outbreak,” writes analyst Yasmeen Rahimi.
Ms. Rahimi writes that while cyclophilin inhibitors are most known for their antifibrotic effects, they also have a compelling antiviral profile, with demonstrated preclinical effects on hepatitis B and hepatitis C viruses, as well as coronaviruses.
“Cyclophilin inhibitors have been specifically implicated in affecting the immune cell activation response in a cell line model of SARS-CoV,” Ms. Rahimi says, adding that since cyclophilin inhibitors impede protein folding, they could also impact viral lifecycle where lots of new proteins are needed for viral replication.
“Since infected patients end up in the ICU with pneumonia that escalates into acute respiratory distress syndrome and diminished lung capacity, the direct-acting antifibrotic properties of CRV431 could be especially important in the context of COVID-19 treatment, in our view,” Ms. Rahimi added.
Hepion recently demonstrated that CRV431 dose-dependently decreased production of procollagen and fibronectin, which can cause fibrotic scarring of injured organs, in cells derived from five different organs.
In addition, CRV431 exerted similar or greater effects than two approved standard-of-care drugs for idiopathic pulmonary fibrosis across many disease markers in a translational research study.
https://biotuesdays.com/2020/03/20/roth-sees-strong-rationale-for-hepion-crv431s-use-in-severe-covid-19-cases/
GLT....
FOLLOW ME AND I WILL FOLLOW YOU REGARDLESS OF OUR PERSONAL OPINIONS.
ALL MY OWN OPINIONS FOR EDUCATIONAL PURPOSES. DO YOUR OWN DD.
Recent HEPA News
- Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial • GlobeNewswire Inc. • 04/19/2024 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 02:02:26 PM
- Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds • GlobeNewswire Inc. • 02/16/2024 01:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:57 PM
- Hepion Pharmaceuticals to Present at NASH-TAG 2024 • GlobeNewswire Inc. • 01/03/2024 10:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 09:30:24 PM
- Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes • GlobeNewswire Inc. • 12/07/2023 01:00:00 PM
- Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit • GlobeNewswire Inc. • 11/28/2023 09:15:00 PM
- Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease • GlobeNewswire Inc. • 11/13/2023 09:05:00 PM
- Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat • GlobeNewswire Inc. • 11/10/2023 01:50:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/09/2023 05:15:08 AM
- Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model • GlobeNewswire Inc. • 10/25/2023 12:30:00 PM
- Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules • GlobeNewswire Inc. • 09/29/2023 12:00:00 PM
- Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference • GlobeNewswire Inc. • 09/21/2023 08:05:00 PM
- New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program • GlobeNewswire Inc. • 09/21/2023 12:00:00 PM
- Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer • GlobeNewswire Inc. • 09/19/2023 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2023 12:00:24 PM
- Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis • GlobeNewswire Inc. • 09/14/2023 12:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 08:40:33 PM
- Hepion Pharmaceuticals Announces Management Changes • GlobeNewswire Inc. • 09/06/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 08:04:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/21/2023 08:41:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/21/2023 08:39:46 PM
- Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023 • GlobeNewswire Inc. • 06/15/2023 08:45:00 PM
- Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat • GlobeNewswire Inc. • 06/15/2023 12:22:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM